AJANTPHARM - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 4.2

📊 Analysis: AJANTPHARM trades at ₹2,633, comfortably above its DMA 50 (₹2,560) and DMA 200 (₹2,588), showing strong technical support. RSI at 53.3 is neutral-to-positive, and MACD (27.5) indicates bullish momentum. Volume (44,920 vs 30,808 avg) confirms intraday liquidity. Fundamentals are strong with high ROCE (33%) and ROE (25.7%), making it a solid candidate for intraday trading.

• 💹 Optimal Buy Price: ₹2,625–2,635 (near current support zone)
• 🎯 Profit-Taking Levels: ₹2,660 (first resistance), ₹2,690 (next resistance)
• 🛡️ Stop-Loss: Below ₹2,610 (to protect against breakdown)
• ⏱️ Exit if Holding: Exit intraday if price fails to sustain above ₹2,620 or if RSI drops below 50 with weakening volume despite positive MACD.

Positive

• ✅ High ROCE 33% and ROE 25.7% reflect strong efficiency.
• ✅ Quarterly profit growth (+6.19%) shows operational improvement.
• ✅ Price above DMA 50 & 200, confirming bullish technical trend.
• ✅ Low debt-to-equity 0.01 ensures financial stability.

Limitation

• ⚠️ P/E 34.6 vs industry 30.6 indicates slight overvaluation.
• ⚠️ PEG ratio 4.36 suggests growth is expensive relative to earnings.
• ⚠️ FII holding reduced (-0.33%), showing foreign investor caution.

Company Negative News

• ❌ Marginal decline in PAT (₹255 Cr. to ₹250 Cr.) despite overall growth trend.
• ❌ Valuation concerns with PEG ratio above fair levels.

Company Positive News

• 🌟 Dividend yield 1.10% supports investor confidence.
• 🌟 Strong efficiency metrics (ROCE, ROE) despite slight PAT decline.
• 🌟 DII holding increased (+0.40%), showing domestic institutional support.

Industry

• 🏗️ Industry PE at 30.6 vs AJANTPHARM PE 34.6 shows slight premium valuation.
• 🏗️ Pharma sector remains resilient with defensive demand and strong fundamentals.

Conclusion

📌 AJANTPHARM is a strong intraday candidate with bullish technicals, solid fundamentals, and liquidity support. Traders may target ₹2,660–2,690 for profit exits while maintaining a disciplined stop-loss near ₹2,610.

Would you like me to extend this into a sector basket overlay with peer benchmarking so you can compare AJANTPHARM against other pharma stocks for intraday rotation opportunities?